Sionna Therapeutics (SION) Stock Price, News & Analysis

Company Overview

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.

Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors. These investigational medicines are intended to stabilize and improve the function of defective CFTR proteins, including proteins affected by the common F508del mutation. The company’s approach is designed to potentially form part of combination therapies that target multiple stages of CFTR production, processing and activity.

Sionna’s pipeline includes preclinical and clinical-stage programs evaluating the safety, tolerability and pharmacological activity of its CFTR modulators. The company’s goal is to develop oral treatments that may benefit a broad population of people with cystic fibrosis, including patients who have limited treatment options because of the specific mutations they carry.

Key Stats

• Today's Range: $5.90 to $7.19
• 50-Day Range: $4.50 to $51.04
• 52-Week Range: $4.01 to $54.97
• Volume: 3.68 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $269.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.33
• Consensus Rating: Hold

Sionna Therapeutics Stock Analysis - MarketRank™

Sionna Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 292nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Sionna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 11 hold ratings, and 1 sell rating.

Upside Potential

Sionna Therapeutics has a consensus price target of $42.33, representing about 610.3% upside from its current price of $5.96.

Amount of Analyst Coverage

Sionna Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sionna Therapeutics are expected to grow in the coming year, from ($2.54) to ($2.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sionna Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sionna Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sionna Therapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.02% of the float of Sionna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sionna Therapeutics has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sionna Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sionna Therapeutics does not currently pay a dividend.

Dividend Growth

Sionna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.00

News Sentiment

Sionna Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Sionna Therapeutics this week, compared to 5 articles on an average week.

Search Interest

16 people have searched for SION on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sionna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,250,367.00 in company stock.

Percentage Held by Insiders

5.10% of the stock of Sionna Therapeutics is held by insiders.

Percentage Held by Institutions

Sionna Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SION
• Previous Symbol: NASDAQ:SION
• CIK: 2036042
• Web: www.sionnatx.com
• Phone: (617) 819-2020
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sionna Therapeutics: $42.33
• High Price Target: $63.00
• Low Price Target: $5.00
• Potential Upside/Downside: +610.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.94%
• Return on Assets: -31.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.05
• Quick Ratio: 20.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.88 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 45,210,000
• Free Float: 42,906,000
• Market Cap: $269.45 million
• Optionable: N/A
• Beta: 0.89